Cognition Therapeutics

Historical price data

Cognition Therapeutics is a neuroscience-focused biotech developing small molecule modulators of the sigma-2 receptor complex to halt synaptic damage in neurodegenerative diseases. Its lead asset, CT1812, has generated encouraging biomarker and cognitive signal in multiple Phase 2 studies in Alzheimer's disease and is also being evaluated in dementia with Lewy bodies. The company's strategy leverages a differentiated mechanism of action, supported by non-dilutive grant funding, to advance its pipeline toward pivotal trials in substantial markets with high unmet need. As a micro-cap public company, its near-term value inflection is tied to the clinical readouts from its ongoing SHINE and SHIMMER trials.

Proprietary platform targeting the sigma-2 (σ-2/TMEM97) receptor complex to protect synapses from toxic protein oligomers in neurodegenerative and neuro-ophthalmic diseases.

Cognition competes in the crowded Alzheimer's space against large pharma with approved anti-amyloid antibodies, but its selective sigma-2 receptor antagonist mechanism is highly differentiated. It is the clinical leader in targeting this receptor for neurodegeneration, with a less crowded field in its secondary indication of dementia with Lewy bodies.